Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Focused Fund median (29 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Aug 2022 – 20 Aug 2026, limited by Edelweiss Focused Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Edelweiss Focused Fund | Nifty 500 |
|---|---|---|
| 03 Aug 2022 | ₹100.00 | ₹100.00 |
| 04 Dec 2022 | ₹106.75 | ₹107.30 |
| 06 Apr 2023 | ₹102.53 | ₹99.20 |
| 08 Aug 2023 | ₹116.10 | ₹113.92 |
| 09 Dec 2023 | ₹127.70 | ₹125.71 |
| 10 Apr 2024 | ₹144.24 | ₹140.58 |
| 11 Aug 2024 | ₹161.24 | ₹154.08 |
| 12 Dec 2024 | ₹170.06 | ₹156.31 |
| 14 Apr 2025 | ₹147.92 | ₹139.49 |
| 16 Aug 2025 | ₹161.02 | ₹152.44 |
| 17 Dec 2025 | ₹165.77 | ₹157.92 |
| 19 Apr 2026 | ₹163.61 | ₹153.71 |
| 20 Aug 2026 | ₹154.46 | ₹158.04 |
| Metric | Edelweiss · Regular · IDCW NAV ₹15.49 Very High risk ★★★★☆ | Category median Focused Fund · 29 funds |
|---|---|---|
| -6.10% | -3.17% | |
| +10.17% | +8.26% | |
| — | +7.82% | |
| — | +4.45% | |
| +11.34% | +9.57% | |
| +6.31% | — | |
| +15.45% | +10.33% | |
| — | +9.22% | |
| — | +4.79% | |
| Risk | ||
| 15.63% | 15.50% | |
| 0.23 | 0.15 | |
| 0.31 | 0.20 | |
| -17.83% | -37.59% | |
| Nifty 500 | — | |
| -1.40% | -2.26% | |
| 0.97 | 0.97 | |
| 89.7% | 87.5% | |
| 93.9% | 100.3% | |
| 2.29% | 2.23% | |
| ₹1,011Cr | ₹2,383Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 29% | 31% | |
| Amit Vora | — | |
| 03 Aug 2022 | — | |
| 29 | — | |
| 51.3% | — | |
| 0.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.